Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRospective Observational Study on PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy (PRO-PAS)

NCT06239415 is registered in ClinicalTrials.gov with Istituti Clinici Scientifici Maugeri SpA as lead sponsor.

NCT NCT06239415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06239415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRospective Observational Study on PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy (PRO-PAS)
Lead sponsor
Istituti Clinici Scientifici Maugeri SpA
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2022
Completion date
March 31, 2024
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral atherosclerotic disease